--- title: 'Director, Medical Affairs Operations at Summit Therapeutics' canonical: 'https://feeny.ai/job/director-medical-affairs-operations-summit-therapeutics-princeton-qnwcxs9r0125' type: 'job' last_seen: '2026-10-30' --- # Director, Medical Affairs Operations at Summit Therapeutics - **Company:** Summit Therapeutics - **Location:** Princeton, NJ - **Compensation:** $190k–$237k - **Posted:** 2026-10-23 - **Last confirmed live:** 2026-10-30 - **Apply:** https://job-boards.greenhouse.io/summittherapeutics/jobs/4462153009 ## Job description About Summit: Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including: Non-small Cell Lung Cancer (NSCLC) - HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC. Colorectal Cancer (CRC) - HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland. ## Overview of Role The Director, Medical Affairs Operations will lead the global Medical Affairs Operations function and provide strategic oversight for the execution of operational activities that support Medical Affairs strategy across regions. This role serves as a key business partner to Medical Affairs leadership and collaborates closely with Compliance, Legal, Finance, Clinical Development, and external vendors to ensure consistent, compliant, and efficient execution of congress sponsorships, advisory boards, scientific engagement programs, healthcare professional interactions, vendor management, contracting, budgeting, systems, and operational excellence initiatives. The Director will establish scalable processes, drive global alignment, manage vendor relationships, build operational capabilities, and oversee a global team supporting Global Medical Affairs operations, while supporting launch readiness, organizational growth, and the successful execution of strategic initiatives across the Medical Affairs organization. ## Responsibilities - Global Medical Affairs Operations Leadership: Lead operational planning and execution of Medical Affairs initiatives across regions, therapeutic areas, and functions. Establish scalable frameworks, policies, processes, and best practices that improve efficiency, quality, compliance, and organizational readiness. - Team Leadership and Development: Lead, coach, and develop a high-performing global Medical Affairs Operations team, including congress sponsorship, US operations, and Europe-based operations roles. Establish goals, performance objectives, development plans, and operating rhythms that support team effectiveness and future growth. - Cross-Functional Partnership and Governance: Partner with regional Medical Affairs leaders, Compliance, Legal, Regulatory Affairs, Finance, Procurement, Clinical Development, IT, and external vendors. Ensure consistent execution of operational processes worldwide and act as an escalation point for operational challenges and cross-functional issue resolution. - Vendor and Financial Management: Oversee Medical Affairs vendor strategy, selection, contracting, performance management, SOWs, purchase orders, budgets, forecasting, and invoice reconciliation. Partner with Finance and Procurement to optimize resource utilization and ensure external engagements follow FMV requirements, company policies, and industry standards. - Congress, Advisory Board, and Scientific Engagement Operations: Provide oversight for national, regional, and international congress sponsorships, exhibits, medical booths, scientific exchange activities, advisory boards, investigator meetings, and individual customer engagements. Establish standardized planning processes, operational metrics, vendor oversight, and resource plans to support consistent execution across regions. - Compliance and Operational Risk Management: Ensure Medical Affairs operations adhere to healthcare compliance requirements, Sunshine Act reporting obligations, FMV standards, company policies, and applicable industry regulations. Maintain audit-ready documentation, monitor emerging requirements, and identify operational risks with appropriate mitigation plans. - Systems, Metrics, and Analytics: Lead development and implementation of dashboards, reports, KPIs, and operational metrics to measure program effectiveness, congress investments, vendor performance, and operational activities. Partner with IT and Digital teams to implement systems and use analytics to identify process improvements and resource allocation opportunities. - Strategic Planning and Launch Readiness: Support annual planning, budget planning, long-range Medical Affairs operational strategy, pipeline expansion, and new product launch readiness. Develop resource and infrastructure plans that enable growth across regions, functions, and therapeutic areas. Experience, Education and Specialized Knowledge and Skills: - Bachelor's degree in Life Sciences, Healthcare, Business Administration, or related field required. - Advanced degree (MS, MBA, MPH, PharmD, or equivalent) preferred. - 10+ years of experience in Medical Affairs Operations, Clinical Operations, Commercial Operations, or related pharmaceutical/biotech functions. - Minimum 5 years of people management experience. - Oncology experience strongly preferred. - Experience supporting both US and international Medical Affairs organizations preferred. - Demonstrated experience supporting pre-launch and launch-stage organizations. - Proven experience managing complex vendor relationships, operational budgets, and cross-functional initiatives. - Strong leadership and team development capabilities. - Excellent project and portfolio management skills. - Deep understanding of healthcare compliance requirements, FMV processes, Sunshine Act reporting, and contracting practices. - Strong financial and budget management expertise. - Ability to operate effectively in a fast-paced, matrixed biotech environment. - Experience implementing operational systems, dashboards, and process improvement initiatives. - Strong analytical and problem-solving skills with a focus on operational excellence. This is the pay for this position Pay Transparency $190,000—$237,000 USD Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation. Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit. Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status. ## About Summit Therapeutics ## Company Overview - **One-liner**: Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel bispecific antibody therapies, with its lead candidate ivonescimab targeting PD-1 and VEGF for multiple solid tumors. - **Entity Type**: Public (NASDAQ: SMMT) - **Headquarters**: Miami, Florida, USA (with additional offices in Palo Alto, CA; Princeton, NJ; Oxford, UK; and Dublin, Ireland) - **Founded**: 2003 - **Founders**: Not publicly disclosed on the company website; the company was founded in 2003. ## Core Business - **Primary industry**: Biopharmaceuticals / Oncology - **Target customers**: B2B (healthcare providers, patients, and caregivers) with a focus on resolving serious unmet medical needs in oncology - **Mission statement**: "To resolve serious, unmet medical needs for the betterment of overall human health." [smmttx.com](https://smmttx.com/company/about-us/default.aspx) ## Products & Services - **Ivonescimab (SMT112)**: A novel, potential first-in-class investigational bispecific antibody targeting both PD-1 and VEGF. It is designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (VEGF blockade) into a single molecule. Currently being studied in several global Phase 3 clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC). Licensed from Akeso, Inc. (HKEX: 9926.HK) for territories including the U.S., Canada, Europe, Japan, Latin America, the Middle East, and Africa. [smmttx.com](https://smmttx.com/pipeline/default.aspx) ## Market Standing - **Valuation/Market Cap**: Approximately $2.7 billion (as of recent data) [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - **Key Metric**: Annual revenue of approximately $705,000 (reported). The company is pre-commercialization and heavily investing in R&D. Total funding raised since IPO (2015) is not disclosed, but the company has a strong cash position from equity offerings. - **Notable Investors/Partners**: Akeso, Inc. (key licensing partner for ivonescimab). The company is publicly traded with institutional and retail investors. - **Growth Signals**: - Headcount grew 72.5% year-over-year to 244 employees. [linkedin.com](https://www.linkedin.com/company/summit-therapeutics) - Multiple global Phase 3 trials actively recruiting (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3, ILLUMINE). - Over 4,000 patients have been treated with ivonescimab across all clinical trials globally. [smmttx.com](https://smmttx.com/pipeline/default.aspx) - Achieved Great Place to Work® Certification. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) ## Competitive Advantages - **Novel Mechanism**: Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, potentially offering superior efficacy and fewer side effects compared to combination therapies. - **Speed and Execution**: The company emphasizes "high-speed execution in commercialization" and has rapidly initiated multiple Phase 3 trials. - **Global Reach**: Licensed territories cover major markets (U.S., Canada, Europe, Japan, Latin America, Middle East, Africa) with a strong partner (Akeso) in the rest of the world. - **Strong Balance Sheet**: With a $2.7B market cap and public listing, the company has access to capital markets to fund its pipeline. ## Strategic Focus - **Current priorities**: Advancing ivonescimab through Phase 3 clinical trials across multiple solid tumor indications (NSCLC, CRC, HNSCC), with the goal of regulatory approval and commercialization. - **Future direction**: Expanding the pipeline into additional solid tumors and leveraging the bispecific platform for future therapies. The company is focused on becoming a leading oncology player. - **Near-term milestones**: Data readouts from ongoing Phase 3 trials, potential regulatory submissions, and building commercial infrastructure. ## Why Work Here - **Culture**: The company has achieved Great Place to Work® Certification, indicating a positive, supportive, and fulfilling work environment. Core values include Commitment to People, Integrity, Passion for Excellence, Purposeful Urgency, Accountability, and Collaboration. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx) - **Work Environment**: Fast-paced, high-energy atmosphere focused on innovation and collaboration. The company emphasizes "making a significant difference in patients’ lives." - **Benefits (U.S.)**: - 401(k) with 6% employer match - Employee Stock Purchase Plan (ESPP) with 15% discount up to the annual federal limit - Flexible Spending Account - Commuter Benefit - Onsite lunch provided - **Benefits (U.K.)**: - Private Medical Insurance - Employee Assistance Program - Life Assurance Policy - Company Pension Contributions - ESPP - **Remote/Hybrid Policy**: Not explicitly stated, but multiple office locations suggest a hybrid or on-site presence is expected for many roles. - **Open Roles**: 25 active job postings (as of recent data) including Senior Director of Sales Operations, Clinical Scientists, Medical Science Liaisons, and Drug Product MSAT roles. [greenhouse.io](https://job-boards.greenhouse.io/summitherrapeutics) - **Headcount Growth**: 72.5% year-over-year growth signals a scaling organization with opportunities for career advancement. ## Sources 1. [smmttx.com - About Us](https://smmttx.com/company/about-us/default.aspx) 2. [smmttx.com - Investor Relations Overview](https://www.smmttx.com/overview/default.aspx) 3. [smmttx.com - Pipeline](https://smmttx.com/pipeline/default.aspx) 4. [smmttx.com - Careers Overview](https://smmttx.com/careers/careers-overview/default.aspx) 5. [linkedin.com - Summit Therapeutics Company Page](https://www.linkedin.com/company/summit-therapeutics) 6. [greenhouse.io - Summit Therapeutics Careers](https://job-boards.greenhouse.io/summitherrapeutics) ## Other roles at Summit Therapeutics - [Director, MSAT-Drug Product (US, UK, Ireland, or Switzerland)](https://feeny.ai/job/director-msat-drug-product-us-uk-ireland-or-switzerland-summit-therapeutics-r3tyakx42enr) — Princeton, NJ - [Senior Medical Science Liaison (Upper NY)](https://feeny.ai/job/senior-medical-science-liaison-upper-ny-summit-therapeutics-new-york-0m9ztt6s208s) — New York, NY - [Medical Writer, Medical Communications & Publications](https://feeny.ai/job/medical-writer-medical-communications-publications-summit-therapeutics-palo-alto-mq4p6tvcrxnt) — Palo Alto, CA - [Senior Manager, Externally Sponsored Research](https://feeny.ai/job/senior-manager-externally-sponsored-research-summit-therapeutics-palo-alto-h6g4ymrm7ret) — Palo Alto, CA - [Paralegal](https://feeny.ai/job/paralegal-summit-therapeutics-palo-alto-7crgxyrgt8ht) — Palo Alto, CA - [Director, Regulatory Affairs CMC](https://feeny.ai/job/director-regulatory-affairs-cmc-summit-therapeutics-remote-spf3wfkhxryb) - [Executive Director, Key Accounts Lead](https://feeny.ai/job/executive-director-key-accounts-lead-summit-therapeutics-field-fcy78qbyss0k) — Field, United States - [Senior Director, Commercial Excellence](https://feeny.ai/job/senior-director-commercial-excellence-summit-therapeutics-princeton-7yyt2trazq5s) — Princeton, NJ - [Senior Director, National Field Excellence](https://feeny.ai/job/senior-director-national-field-excellence-summit-therapeutics-united-states-tbfnrz5523j2) — United States - [Associate Director, Site Alliances and Strategy](https://feeny.ai/job/associate-director-site-alliances-and-strategy-summit-therapeutics-remote-k0p2pnwxn3bb)